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1Introduction
Influenza in HIV positive patients
Influenza illness is a worldwide, public health problem 
of major concern. It is a highly contagious, ubiquitous 
disease that can lead to severe complications, especially 
in the elderly, debilitated or chronically ill patients, chil-
dren and in immunosuppressed subjects, including those 
infected with the human immunodeficiency virus (HIV) 
and transplant recipients [1, 2]. It is difficult to estimate 
hospitalizations and deaths due to influenza and its com-
plications because infections are not often confirmed vi-
rologically or specified on hospital discharge forms or 
death certificates [3]. For influenza disease a significant 
burden lies on all individuals, but hospitalization and 
treatment occur more frequently in high-risk patients. In 
addition to the clinical burden, influenza also poses a 
considerable economic burden. There are extensive eco-
nomic analyses of the influenza burden in the literature. 
One study estimated a total economic burden of seasonal 
influenza in the United States (using 2003 population 
and dollars) to be $87.1 billion, including $10.4 billion 
in direct medical costs [4]. In addition to the direct costs 
of medical care, the indirect costs of influenza are sub-
stantial due to the increase morbidity. The burden of in-
fluenza varies with the age and underlying health of the 
patient. Estimates of the cost of influenza in the USA, 
France and Germany have shown that indirect costs can 
be five– to 10–fold higher than direct costs [5]. In par-
ticular, influenza remains a common cause of respira-
tory illness in adults with HIV, despite the use of novel 
high retroviral therapies and increase of flu vaccine 
coverage rate, that lead the mortality rate from 2.2 mil-
lion (in 2005) to 1.8 million (in 2010) [6, 7]. The studies 
conducted by Neuzil et al. and Lin et al. confirmed high 
numbers of hospital admissions and high mortality from 
influenza in patients with HIV/AIDS not on Highly Ac-
tive Anti Retroviral Therapy (HAART) [8, 9]. Neuzil et 
al., in another study reported that cardiopulmonary hos-
pitalisations in influenza infection of patients with  Ac-
quired Immunodeficiency Syndrome (AIDS)/HIVwere 
very high in the pre-HAART era, with a rate of 48 per 
1000 persons; in the post-HAART era hospitalisation 
rates decreased by 53% but remained more higher than 
that of the U.S. population and similar to that of the pop-
ulation at risk [10].
Immunization against influenza can effectively reduce 
the annual clinical and economic burden of influenza. 
Nevertheless, despite efforts to vaccinate those at high-
est risk of severe influenza-related complications, many 
still go unvaccinated [11, 12]. A study in eleven Euro-
pean countries showed that the highest immunization 
coverage for the population considered at high risk, was 
reached in the Netherlands (about 80% of vaccinated 
subjects), while the lowest rate belongs to Greece with 
only 25%. This data may be explained by several consid-
erations: first, factors such as education can guide people 
towards a particular choice in favor of vaccination or not; 
second, in some countries the reimbursement for the cost 
of vaccination is partial; third, a smaller number of doses 
distributed could obviously result in a smaller number of 
subjects vaccinated  [12]. The Advisory Committee on 
Immunization Practices considers HIV-infected persons 
to be at increased risk for influenza and recommends an-
nual vaccination [13]. In view of mortality , morbidity 
and complication risk, already in 1986 there was a rec-
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Summary
Annual influenza vaccination is recommended for persons with 
human immunodeficiency virus (HIV) infection. Recent reports indi-
cate that immunizations may increase HIV replication in infected 
individuals. Generally, vaccination against influenza is well toler-
ated in both children and adult individuals with HIV and does not 
induce significant changes in viral load and CD4+ cell counts. The 
observed increase in viral replication is usually transient and a 
clear, measurable progression of the underlying HIV disease is hard 
to be determined. Several studies reported immunogenicity data in 
HIV+ population, by comparing different influenza vaccines, adju-
vanted or not, and different administration routes. Data are encour-
aging because an adequate immune response is shown, although 
split/subunit vaccines do not elicite an efficient immune response in 
these subjects. New strategies have been evaluated to increase the 
immune response in immunocompromised patients.The aim of this 
review is to evaluate tolerability, safety, immunogenicity and effi-
cacy of vaccines actually approved for human use and to consider 
latest evidence and future perspective in HIV positive subjects.
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ommendation for influenza vaccination of patients with 
human T- lymphotrophic virus type III AIDS-related, 
and since 1988 the CDC recommended vaccination in 
children with acquired immunodeficiency syndrome. 
Current guidelines recommend that individuals infected 
by HIV receive yearly influenza vaccination. Since most 
previous studies on influenza vaccines in HIV infected 
individuals focused on their immunogenicity rather than 
on their clinical effectiveness, it is crucial to set up close 
post vaccination influenza monitoring to check the per-
sistence of immune response and effective immune pro-
tection against viral strains circulating during seasonal 
epidemics [14-16].
The Strategic Advisory Group of Experts (SAGE) on 
immunization reviewed evidence on influenza disease 
burden, vaccine performance (efficacy and safety), and 
the feasibility and cost-effectiveness of implementing 
vaccination programmes for population groups at higher 
risk. In 2012, WHO published updated recommenda-
tions for seasonal influenza vaccination based on a sys-
tematic literature review performed by SAGE [17-21].
SAGE confirmed the recommendations to consider as 
priority groups for influenza vaccination individuals > 6 
months with chronic heart or lung diseases, metabolic or 
renal disease, chronic liver disease, chronic neurological 
conditions and immunodeficiencies. 
Prospective studies have looked at the long-term effect 
of influenza vaccination, confirming the safety and tol-
erability of currently used influenza vaccines, but ques-
tions remain about the immunogenicity and effective-
ness of these vaccines in HIV infected patients. New 
roads could be opened through the use of new vaccines, 
such as MF59® adjuvant and those administered intra-
dermally, that could overcome problems such as poor 
immune response and suboptimal effectiveness [22, 23]. 
The aim of this review is to evaluate tolerability, safety, 
immunogenicity and efficacy of vaccines actually ap-
proved for human use and to consider latest evidence 
and future perspective in HIV- positive subjects.
Tolerability and safety
Several studies were performed to evaluate tolerability 
and safety of influenza vaccination in HIV positive pa-
tients showing a good tolerability profile. In different 
studies reported symptoms resolved without sequelae in 
few days. There is lack of data regarding adverse events 
at long-term [23, 24].
Main evidence emerged by safety and tolerability evalu-
ation of available vaccines in the last decade; serious ad-
verse events, systemic and local reactions are reported 
below.
Serious adverse events
Serious adverse reactions were defined as any untoward 
medical event that at any dose result in death or is life-
threatening, requires hospitalisation, results in disabil-
ity or congenital anomaly [25]. From global analysis of 
more than 20 studies that evaluated safety and tolerabil-
ity profile, no serious adverse events (SAEs) are tight 
associated with influenza vaccination in HIV- infected 
patients. Reported adverse events during follow-up of 
the studies were not associated with influenza vaccina-
tion but usually related to syndromes or treatment as-
sociated with HIV. 
Trivalent Influenza Vaccines (TIV) were the first and 
the most used vaccine for immunization of HIV posi-
tive subjects. As emerged from literature data of the last 
two decade, TIV showed a good safety profile and no 
SAEs were reported [26, 27]. Durando et al., compare 
two influenza virus subunit vaccines with or without 
MF59® adjuvant showing absence of serious adverse 
event, except for a case of transitory ischemic attack in 
a men, episode that was demonstrated to be not correlate 
to vaccination [28]. Cooper et al., in his study, using a 
trivalent killed split not adjuvanted influenza vaccine in 
HIV infected adults, showed that vaccination is well tol-
erated without increase reactogenicity as consequence 
of higher antigen dose or boosting dose. In his study 
the population is divided into three groups, the first of 
which received one dose of influenza vaccine (0.5 mL 
or 15 µg hemagglutinin [HA]) in October and November 
2008 followed by a booster dose 28 days later, while the 
second gets a double dose (30 µg HA) at the same time 
interval, followed by a double dose of booster 28 days 
later and finally, the third group received a single dose 
of vaccine [29].
Several studies conducted in HIV infected individuals 
immunized with A(H1N1) 2009 pandemic inactivated, 
unadjuvanted vaccine showed that vaccines were safe 
and well tolerated in this population and no SAEs were 
reported. Crum-Cianflone et al. evaluated a monova-
lent non adjuvanted 2009 influenza A/H1N1 vaccine 
comparing SAE in HIV positive and uninfected sub-
jects showing that only 1 partecipant (HIV- uninfected 
patients) developed a serious adverse event that consist 
in angioedema on day 1 post vaccination and resolved 
after 17 days with antihistamine therapy  [30]. It  also 
occurred eight hospitalization but no one related to 
vaccination (seven in HIV-positive patients and one in 
healthy subjects)  [31-41]. It has been demonstrated in 
studies involving a total of 892 children and 111 adults 
that administration of live attenuated influenza vaccine 
(LAIV) vaccine is safe and well tolerated and not seri-
ous adverse events related to vaccination were recorded. 
Furthermore, the safety profile is very similar to that pre-
viously reported in studies including other populations. 
Current influenza vaccination guidelines do not recom-
mend LAIV immunization in persons with known or sus-
pected immunodeficiency diseases, but the cited studies 
demonstrated that this vaccine should be evaluated for a 
role in immunizing HIV infected people [42-47]. 
Data from existing studies showed that virosomal in-
fluenza vaccination is well tolerated and no complaints 
of severe adverse reactions are usually reported in both 
children and adult HIV positive individuals [26].
Gabutti et al., and Durando et al., in their study do not 
show adverse serious events associated with the vacci-
nation during the follow up period in HIV populations 
vaccinated both with MF59® influenza vaccine and with 
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subunit vaccine containing 15 µg of HA per strain and 
administered intramuscularly [26, 28].
In the study by Launay et al., three adverse reactions are 
reported after 42 days post vaccination, with monova-
lent 2009 Influenza A/H1N1v vaccine adjuvanted with 
AS03®, consisting of hospitalization following the sec-
ond dose of adjuvanted vaccine, one recurrent episode of 
depression and one increase in serum alanine transami-
nase value associated with other treatment [48]. Palma 
et al., evaluating safety and immunogenicity of mono-
valent adjuvanted A/H1N1 pandemic influenza vaccina-
tion reported no deaths or serious adverse event during 
the follow-up [49]. No correlation between SAE and in-
fluenza vaccination was observed. Many studies report 
that the pandemic vaccine with or without adjuvant is 
safe and well tolerated [32-35, 38, 39, 48, 50-52].
Gelinck et al. also reported no adverse events in the 
study which compares the influenza vaccine contain-
ing 0.1 ml of the 2005/2006 trivalent influenza vaccine 
administered intradermally and 0.5  ml administered 
intramuscularly in immunocompromised patients. The 
frequency of events is more higher in subjects who re-
ceived the vaccine intramuscularly [22]. The same ob-
servation were reported by Ansaldi et al., in a study in 
which intradermal vaccination low-antigen – 9 µg HA 
per strain- and vaccine intramuscular containing a stan-
dard dose of antigen -15 µg- were administered to HIV 
positive patients and compared. The study, although the 
low population size, shows good safety for both vac-
cines and no SAE [53].
Systemic reactions
Systemic reactions occur after a few hours of vaccina-
tion and may last for 24-36 hours. They may be linked 
to various causes such as the action of endotoxins, repli-
cation “in vivo” of microorganisms , the toxicity of the 
adjuvant and the reactivity of the immune system. They 
are usually mild, but in some cases can be so severe as to 
require supportive therapy. 
Durando et al., comparing two subunit influenza vac-
cines with or without MF59® adjuvant, in patients with 
immunodeficiency acquired, reports such as systemic 
event most widespread headaches and fever in both 
groups with percentages of 25.9% and 28.4% [28].
In different studies, adverse systemic effect in patient 
vaccinated with virosomal influenza vaccine are com-
parable to subunit influenza vaccine group. In particular 
Evison et al., reported in a population of immunosup-
pressed adults vaccinated with a subunit or a virosomal 
influenza vaccine that the fatigue was the most frequent-
ly reaction, followed by headache and malaise in both 
vaccine group [54].
Systemic reactions typically occur after a few days post 
vaccination and are more frequent in subjects receiving 
an adjuvanted vaccine. They are mild or moderate and 
of short duration. 
Indeed, Gabutti et al., comparing two influenza vaccine 
containing 15 µg of superficial haemagglutinin antigen 
for strain, MF59®-adjuvanted influenza vaccine (group 
A) versus a conventional subunit vaccine (group B), re-
ports fever in 5% of patients of group A and 10% of 
subjects of groups B [26].
Palma et al., reports in his study as most frequent sys-
temic reactions headache, fatigue and chills. 8% of sub-
jects reports fever , 11% fatigue after the first dose. Fe-
ver is not reported after the second dose, while fatigue 
reported by 6% of subjects [49]. 
Gelinck et al., comparing 156 immunocompromised pa-
tients and 41 healthy controls that were randomized to 
receive either 0.5mL of the 2005/2006 trivalent influen-
za vaccine intramuscular or 0.1mL intradermal, estimat-
ed the frequency of adverse reactions after intramuscular 
vaccination with symptoms going from muscle pain to 
fever with values  ranging from 11-48% [22].
Local reactions
Local reactions are defined as reactions that occur at the 
site of inoculation of the vaccine and determine redness, 
pain, erythema, pruritus. In general the local reactions 
are more frequent in subjects vaccinated with adjuvan-
ted or intradermally administered influenza vaccines.
LAIV were well tolerated and have a similar safety 
profile compared with TIV; nasopharyngeal symptoms 
were minor and of short duration.
Durando et al., comparing two subunit vaccines with 
or without MF59® adjuvant, in patients with immuno-
deficiency acquired, reports such as local event most 
widespread pain an induration, respectively 54.3% and 
22% [28].
Among the adverse local effect in patient vaccinated 
with virosomal influenza vaccine, the pain is the most 
frequent local reaction, followed by swelling and red-
ness. Reported adverse events were comparable with 
those recorded in the groups immunized with conven-
tional vaccines.
Some studies that use an adjuvanted vaccine (MF59®) 
and where the population was immunodepressed (HIV 
positive or those with chronic illnesses) reported lo-
cal reactions of mild or moderate entity [24, 41, 42]. In 
the study by Launay et al., use of adjuvanted vaccine 
with aluminum salts determine a higher rate of reac-
tions (71%) in HIV positive subjects compared to the 
control group (21%) [48]. Gabutti et al., comparing the 
safety and immunogenicity of a subunit vaccine versus 
MF59®-adjuvantated vaccine in HIV-positive patients, 
reported pain and redness in 28% of patients vaccinated 
with adjuvantated vaccine and 10% of subjects vacci-
nated with the subunit vaccine [26].
The most frequent local effect were pain -18%-, swell-
ing and redness -2%- at injection site. Were classified 
as mild and resolved in few days post vaccination, as 
reported by Palma et al. [49].
Ansaldi et al. in his study reported pruritus in 29% ID vs 
4% IM, redness 46% vs 8%, swelling 43% vs 12%. All 
local events were mild or moderate and resolved without 
sequelae [53].
The same conclusions are reached by Gelinck et al. in 
their study in which they evaluated the administration 
of a trivalent vaccine by intradermal route (0.1 ml) or by 
intramuscular (0.5 ml), they reported erythema and pain 
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at the injection site 48 hours after vaccination showing 
these reactions more frequently in subjects vaccinated 
intradermally and in the control group compared to im-
munocompromised patients. In general, all subjects in 
the control group and 69% of immunocompromised in-
dividuals who responded to all three antigens showed a 
local skin reaction [22].
HIV-RNA and CD4+ cell count post-vaccination
Several studies published between 1995 and 2012 re-
ported controversial data both in favour and against 
the evidence of increase of viral load and a decrease 
of CD4+ cell count secondary to the administration of 
influenza vaccination in HIV infected persons with or 
without correlation to the immune response. Differ-
ences in used vaccines, in sample sizes and features of 
HIV infected populations (i.e. demographic character-
istics, risk factors, stage of HIV disease, patients under 
anti-retroviral treatment or naıve) enrolled in the various 
studies as well as timing of sampling assays and differ-
ent sensitivity of laboratory methods for quantification 
of viral load, could explain at least part of these conflict-
ing reports [32, 41, 43].
Many authors reported an increase in viral load fol-
lowing influenza immunization, this data appears to 
be related to detectable viral load at baseline and no 
treatment of HAART therapy, although it is not al-
ways observed [24, 27, 55-59, 61-63]. The rebound 
of viral load is attributed to activation of quiescent HIV 
infected CD4+ cells and the up regulation of HIV viral 
replication [52, 58-62]. 
Günthard et al. and Staprans et al. showed that effects of 
trivalent influenza vaccine on viral replication in HIV 
positive adults determined transient increase of plasma 
HIV-RNA levels  [58,  64]. Therefore, the simultane-
ous decrease in pro-viral DNA and memory phenotype 
CD4+ cells in association with increased plasma HIV 
RNA after vaccination in patients with < 400 RNA cop-
ies/ml at baseline suggested that in vivo mobilization of 
the latently infected cell reservoir may occur during po-
tent antiretroviral therapy [58]. The same conclusion has 
been reported by Fuller et al. and Madhi et al. [56, 65].
Study conducted in HIV infected children reported con-
troversial data about increase of viral load after immuni-
zation with trivalent influenza vaccine.
Kosalaraska et al. showed an increase in HIV-RNA lev-
els in children aged ≥ 6 months to < 18 years: authors 
stated that increase in plasma HIV-RNA was a tran-
sient phenomenon and did not have any clinical signifi-
cance [66]. Machado et al. showed no increase neither 
in viral load nor in CD4+ cell count in a population of 
children with a mean age of 12 years [67]. 
In the study by Tasker et al. CD4+ cell count and viral 
load are evaluated in HIV positive subjects vaccinated 
with LAIV influenza vaccine. They showed an increased 
HIV replication and a decrease in CD4%: according to 
the authors, this effect is probably due to the absence of 
treatment with antiretroviral therapy [63].
Levin et al., showed, instead, no significant increase 
from baseline in plasma HIV viral load and no change 
in CD4% in HIV infected children aged ≥ 5 months to < 
18 years old [44]. Studies in HIV-positive adults immu-
nized with a monovalent unadjuvanted influenza vac-
cine (H1N1) administered with a single dose, reported 
no significant change in plasma HIV RNA levels or 
CD4+ cell count [30, 32].
Tanzi et al. evaluating effects of a virosomal influen-
za vaccine on viral replication and T-cell activation in 
HIV–infected children, receiving HAART, observed no 
increase in plasma HIV-1 RNA or HIV-1 pro-viral DNA 
and the immunophenotype analyses demonstrated that 
CD4+ cell counts and percentages and activated lym-
phocytes remain stable for about a month after immuni-
zation [68].Same results have been obtained by Zuccotti 
et al., Zanetti et al. and Esposito et al.  [24, 69, 70]. In 
the study by Amendola et al., the mean viral RNA levels 
did not change in HIV infected and uninfected adults as 
well as no difference have been showed in HIV proviral 
DNA levels [25].
However, more recent and better designed studies have 
not documented a substantial increase in the replication 
of HIV, immune stimulation resulting from influenza 
vaccination did not significantly change the levels of 
plasma virus, CD4+ cell counts, or activation-induced 
apoptosis in HIV-infected individuals. An increase in 
the T-cell response to influenza and spontaneous apop-
tosis, and increase in plasma HIV-1 RNA level follow-
ing influenza vaccination are rare and transient phenom-
enon [43-45, 52, 56, 60, 61].
Different studies evaluated the effects of adjuvanted sea-
sonal and pandemic influenza vaccine on HIV viral load 
and CD4+ cell count in HIV positive subjects. Vaccines 
used in this studies were adjuvanted with oil-in-water 
emulsion, in particular with MF59® and AS03®, the 
only adjuvants approved for human use. Gabutti et al. 
by comparing groups mean lymphocyte count for time 
points after immunisation didn’t reveal any statically 
significant changes in HIV positive adults immunized 
with MF59 adjuvant or conventional influenza vaccine, 
with the exception of subjects with lymphocyte counts 
< 200 cells/mm3, vaccinated with conventional subunit 
vaccine, whose counts showed a progressive increase 
after immunization [26]. Durando et al. in HIV positive 
adults showed a decrease of HIV RNA and an increase 
of CD4 cells in subjects immunized with adjuvant vac-
cine compared to patients immunized with conventional 
not adjuvanted influenza vaccine  [28]. Iorio et al. re-
ported, no substantial change in viral load and transi-
tory increase of HIV replication in subjects immunized 
with a conventional vaccine although the study popu-
lation were immunized with the same formulation of 
the above-mentioned study  [71]. Palma et al., in HIV 
positive children and adults immunized with a monova-
lent pandemic adjuvanted influenza vaccine, showed no 
altered CD4 count and HIV viral load levels  [49]. As 
regard as influenza vaccines adjuvanted with AS03®, 
Calmy et al., Tremblay et al. and Launay et al. observed 
a transient increase of HIV-1 RNA replication within 
days of the vaccination, but neither increased risk of 
disease progression nor long-term effects on CD4+ cell 
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counts, viral load, or progression to AIDS or death have 
been reported [48, 51, 52].
Lack of data exists in the literature regarding the ef-
fect of influenza vaccination with intradermal deliv-
ered; therefore, further studies of this preparation are 
needed.
Immunogenicity
Typically, to evaluate the immunogenicity of influenza 
vaccines are considered the following parameters:
Geometric mean titres (GMTs), mean- fold increase in 
titres (MFI; ratio of post to pre- vaccination titre), se-
roprotection rate, defined as the percentage of subjects 
achieving a significant increase in titre from a non-neg-
ative pre-vaccination titre (≥ 1:10) or a rise from < 1:10 
to ≥ 1:40 in those who were seronegative), and serocon-
version rate defined as either a negative pre-vaccination 
titer (≤ 10) to a post-vaccination titer ≥ 40, or at least a 
fourfold increase between pre-and post-vaccination ti-
ters where the pre-vaccination titer is ≥ 10. The Com-
mittee for Medicinal Products for Human Use (CHMP; 
formerly CPMP) criteria for approval of influenza vac-
cine in adults younger than 60 years includes that at least 
one of the following criteria are met: seroprotection rate 
> 40% , MFI > 2.5 or seroconversion rate > 70% [72]. 
As recommended by the WHO the test used to assess the 
immunogenicity of influenza vaccine are the inhibition 
of hemagglutination (HI) and microneutralization (MN) 
assay  [17]. 
The HI assay has been used as the primary means to 
measure serum antibody responses to influenza vaccines 
due to the ease of conducting the assay and a gener-
ally accepted correlation with seroprotection. However, 
the information imparted by a demonstration of neu-
tralization capacity is different from that of HI, which 
measures disruption of binding to red cells without as-
sessing prevention of infection. Although definitive 
human studies are lacking, animal models suggest that 
neutralization capacity predicts prevention of infection, 
while HI correlates with prevention of disease [45, 46]. 
In clinical trials of vaccines, MN assays may be more 
sensitive in detecting antibody and demonstrating sero-
conversion [54, 73] , including in immunocompromised 
subjects. HIV infection is associated with deficiencies 
in both humoral and cell-mediated immunity, which can 
alter the course of common infections and influence vac-
cine immunogenicity  [74]. Generally in HIV-infected 
patients immunogenicity correlates directly with CD4+ 
cell count and inversely with HIV viral load [57, 58].
Most studies emphasized the importance of a high CD4+ 
cell count, treatment HAART therapy and use of adju-
vant influenza vaccine to increase vaccine response rate; 
The immune response is closely correlated to the degree 
of immunosuppression [28, 35, 71, 75]. Hatayema et al., 
Fig. 1. Seroprotection rate in studies involving hIv + population.
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instead, in his study observed no correlation between 
plasma HIV RNA levels and HI antibody response [31]. 
Figure 1 shows the seroprotection rates of some studies 
reported in this review.
Conventional and LAIV influenza vaccines
As regard as non-adjuvanted A(H1N1)2009 pandemic 
vaccine, several studies evaluated antibody responses 
elicited by this vaccine in different populations of HIV 
infected individuals. Most of study participants followed 
an antiretroviral therapy with an high median CD4+ T-
cells counts and fully suppressed HIV-RNA levels. 
Despite a good safety and tolerability profile, antibody 
responses elicited by conventional pandemic vaccine 
were insufficient to confer adequate protection in this 
immunosuppressed, hyporesponsive, at high risk sub-
jects [30, 41].
The collected data regarding the administration of in-
fluenza unadjuvanted vaccine are controversial: Lagler 
et al. and Hatakeyama et al., reported in HIV posi-
tive adults a low immune response after two doses of 
pandemic influenza vaccine, while Bickel et al. and 
Cooper et al., demonstrate the effect of a booster dose 
of pandemic influenza vaccine in HIV-positive adults 
plays a fundamental role to increase the immunogenic-
ity in immunodepressed population  [31,  39,  41,  76]. 
Some authors evaluated the effect of a single dose of 
non-adjuvanted pandemic vaccine obtaining contro-
versial results: some authors reported an adequate im-
munogenicity while others suggested that new strate-
gies would be evaluated [30 32, 34, 36, 37, 40, 77]. As 
regards the evaluation of the immunogenicity of non-
adjuvanted pandemic vaccine in children, Phongsamart 
et al., Flynn et al. and Hakim et al. reported an ade-
quate immune response after two doses. Phongsamart 
et al., in his study showed a low level of cross reacting 
antibody to seasonal H1N1 [33, 35, 38].
Immunogenicity evaluations of LAIV in HIV infected 
population derived from a few studies. 
In HIV infected children further evaluations of LAIV 
are needed, because conflicting data exist about anti-
body responses to vaccination. Two comparative studies 
showed that TIV elicited a seroconversion rate higher 
than LAIV, although the proportions of subjects with 
protective titers were similar between groups. In particu-
lar Weinberg A et al., demonstrated that TIV was more 
immunogenic than LAIV both against homotypic and 
heterosubtypic viruses, using microneutralization and 
haemagglutination inhibition assays. A study by King 
JC et al., showed a similar seroconversion rate after two 
doses of LAIV immunization both in HIV infected and 
uninfected children. In HIV infected adults only one 
study reported data about immunogenicity elicited by 
LAIV vaccine, but the low size of study population does 
not allow appropriate conclusions [42, 46]. 
A limited number of studies reported results of immu-
nogenicity for virosomal influenza vaccination, in popu-
lations of adults and children. All studies reported that 
HIV positive subjects show lower immune responses to 
influenza vaccination in comparison with immunocom-
petent individuals. Seroconversion rates of HIV infected 
populations elicited by virosomal influenza vaccines do 
not differ significantly from that produced by trivalent 
conventional vaccines.
Tanzi et al., showed that use of the virosomal influ-
enza vaccine is moderately immunogenic in HIV in-
fected children. Because there are no EMEA defined 
criteria for children, immunogenicity was evaluated us-
ing criteria for adult. Humoral immune response were 
adequate for all three influenza strains in primed chil-
dren and adequate for the two A strains in groups of the 
unprimed [68].
Oil-in-water emulsion adjuvanted influenza vaccines
Immunogenicity of MF59 adjuvanted influenza vaccine 
has been evaluated in different HIV positive popula-
tions. The different studies were designed and carried 
out in different manners: in literature there are compara-
tive and not comparative, prospective trials, and popula-
tions involved varied from infected/uninfected children 
to infected/uninfected young adults and adults. Several 
studies showed that MF59 adjuvanted influenza vaccine 
had good safety and immunogenicity profiles similar or 
better than conventional influenza vaccine. All studies 
underlined that CD4+ cell count and HAART treatment 
play a key role in determining antibody response in in-
fluenza vaccination. Three studies reported a compari-
son between MF59 adjuvanted and conventional non 
adjuvanted seasonal influenza vaccine in HIV positive 
adults.
In the study by Durando et al. an assessment of humoral 
and cell-mediated immune responses elicited by the two 
influenza vaccines was made. Immunocompromised 
individuals vaccinated with MF59 adjuvanted vaccine 
showed a better antibody response and also a statistical-
ly significant increase in the frequency of proliferating 
T cells at 30 days after immunization, compared with 
patients vaccinated with non adjuvanted vaccine. HIV-
negative subjects mounted a stronger antibody response 
than HIV-positive subjects [28].
The same results were obtained by Iorio et al. by com-
paring the immune response elicited by the same vac-
cines in HIV patients under antiretroviral therapy [14]: 
MF59 adjuvanted influenza vaccine induced a better im-
mune responses as compared with conventional vaccine 
in HIV positive HAART treated subjects [71].
Gabutti et al. compared the antibody responses elicited 
by an MF59 adjuvanted and a conventional subunit in-
fluenza vaccine in 37 HIV positive patients population, 
showing not significant differences between the two 
immunised groups and as regard as the three different 
influenza strains. An important aspect of the study was 
the prolonged persistence of specific antibodies versus 
all the vaccine strains: 51.7% of MF59 patients and 
59.7% of subunit patients showed a seroprotective lev-
el of antibodies even 180 days after immunization [26].
During the last three years, several studies evaluated the 
performance of MF59 adjuvanted pandemic vaccine in 
HIV positives children and adults [49, 75, 78, 79, 81]. 
Both in adults and in children the immune response 
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stimulated by a single or two doses of pandemic MF59 
adjuvanted influenza vaccine was comparable in HIV 
infected patients and in healthy controls. In the study 
by Kajaste-Rudnitski et al. the seroconversion rate ob-
served after a single dose of MF59®-adjuvanted influ-
enza vaccine was lower in the HIV positive individu-
als as compared with HIV negative controls; however, 
the seroprotection rates were similar in both study 
groups  [80]. Soonawala et al. reported the induction 
of cross reactive antibodies to pH1N1 after vaccina-
tion with seasonal TIV in HIV infected adults: authors 
hypothesized that HIV infected patients could produce 
larger quantities of cross reactive antibodies after vac-
cination because of a less well regulated B-cell immune 
response [75]. Palma et al. and Viganò et al. evaluated 
the immunogenicity of MF59®-adjuvanted pandemic 
influenza vaccine in HIV positive children and young 
adults, showing adequate levels of seroprotection al-
ready after a single dose; however, authors suggested 
a two-dose vaccination schedule in this population, in 
order to optimize and obtain a long-term antibody re-
sponse [49, 81].
Thus, MF59®-adjuvanted influenza vaccine should be 
considered for use in HIV positive adults and children, 
because it could improve the effectiveness of influenza 
vaccination programmes in this population, who are at 
high-risk of influenza-related complications.
Another oil-in-water emulsion used as adjuvant in influ-
enza vaccine is the AS03 adjuvant system. The AS03® 
adjuvant consisted of a 10% oil-in-water emulsion 
based adjuvant system, containing 5% dl-α-tocopherol 
(11.86 mg) and squalene (10.69 mg) in the oil phase 
and 2% of the non-ionic detergent Tween®80 (4.86 mg) 
in the aqueous phase. Recently, the AS03® adjuvant has 
been adopted in the licensed formulation of a H1N1 
2009 pandemic vaccine. Some authors [51, 82] report-
ed seroprotection rates lower after one dose of AS03 
adjuvanted vaccine (61% to 75%) in HIV infected 
adults [51, 82, 83], while a second dose determines an 
increase up to 97.7% [76, 84]. According to these au-
thors this difference could be attributed to the different 
timing of immunization during the pandemic outbreak, 
in relation to higher baseline or follow-up seroprotec-
tion rates. Concerning the seroconversion rates, other 
studies reported values  of 88% to 95.3% after a single 
dose in HIV positive patients [48, 84, 85]. The collect-
ed data regarding the administration of a single dose of 
influenza AS03 adjuvanted vaccine are controversial: 
Manuel et al., reported a similar immune response in 
HIV patients and healthy control, while Kelly et al., 
showed that immune response correlate with a pre- ex-
isting antibodies and a single dose may be insufficient 
to induce protective immunity  [86,  87]. Okike et al., 
reported that the use of ASO3 adjuvant in HIV posi-
tive children have likely played an important role in 
eliciting the high sero-response rates [50]. In general, 
the use of AS03 adjuvanted pandemic vaccine in HIV 
positive immunocompromised patients may lead to the 
expansion of coverage and increase the immune re-
sponse [55, 83].
Intradermal influenza vaccines
Between strategies implemented to increase the immu-
nogenicity of influenza vaccination in HIV patients, in-
tradermal approach is also to be mentioned. In persons 
with impaired immunity intradermal vaccination is of 
particular interest because of different immunologic ad-
vantages.
The dermis harbours a network of antigen presenting 
cells, constituting up to 2% of all dermal cells, which 
forms an optimal environment to deliver a vaccine. In 
the study by Gelinck et al., 39 HIV positives adults 
received the 2005/2006 trivalent influenza vaccine de-
livered intradermally according to the CDC guidelines, 
using an intradermal injection syringe (BD Micro-Fine 
0.5 ml U-100 insulin syringe) and needle (29G), also 
used for intradermal tuberculin injections. The intrader-
mal vaccine dose contained 3 mg of haemaglutinin of 
the three strains. The intradermal vaccination with a low 
dose resulted in similar postvaccination titers as com-
pared to standard intramuscular vaccination in the study 
groups: in particular only the HIV group had higher ti-
ters after intradermal vaccination. Results suggested that 
the intradermal vaccination is more efficient in inducing 
an immune response compared to intramuscular vacci-
nation in HIV infected patients [22].
The superiority of the immune response elicited by the 
intradermal vaccine is shown by the values  of the rates 
of seroprotection, seroconversion, and MFI/GMRT all 
higher than the vaccine administered intramuscularly to 
the controls. Ansaldi et al., in his study compared immu-
nogenicity of licensed intradermal trivalent inactivated 
split vaccine delivered by licensed microsystem device 
with a lower antigen content (9 µg HA per strain) against 
the conventional intramuscular (15µg) influenza vaccine 
in a population of 54 HIV infected adults. Both vac-
cines meet the criteria for MFI and seroprotection rate 
but not for seroconversion against the B virus, there are 
no differences in terms of post-vaccination GMT /MFI, 
seroprotection and seroconversion rates comparing the 
two vaccines. The results of this trial showed that the 
licensed low antigen content ID vaccine was safe and 
immunogenic in HIV positive adults, although the small 
sample size of the study [53].
Conclusions
Influenza is a major cause of death, hospitalization and 
disability in immunocompromised population, resulting 
in an health and economic burden that may be reduced 
implementing annual vaccination as recommended by 
WHO guidelines.
The considerable experience accumulated about influ-
enza vaccination refers a good safety and tolerability 
profile, in fact the adverse events reported are usually 
mild and resolve in a few days after their appearance.
About the vexed question of viral load increase, conflict-
ing data are reported in literature. However, when this 
increase occurs, it is of transient nature and typically did 
not associate in CD4+ T cell counts changes.
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Some studies reported immunogenicity data in HIV+ 
population, in which are compared different influenza 
vaccines, adjuvanted and not, and different administra-
tion routes.
The data are encouraging because an adequate immune 
response is shown, although split/subunit vaccine do not 
elicited an efficient immune response in these subjects.
New strategies were evaluated to increase the immune re-
sponse in immunocompromised patients, as increase dos-
age, multiple dose vaccination, use of vaccine adjuvant, 
immunostimulant patches (the skin, especially its epider-
mal layer, is an accessible and competent immune environ-
ment and an attractive target for vaccine delivery, through 
transcutaneous delivery or immunostimulant patches) and 
different routes of vaccine delivery transcutaneous im-
munization, a topical vaccine application, combines the 
advantages of needle-free delivery while targeting the im-
munologically rich milieu of the skin [64, 70, 88, 89]. The 
administration of an MF59®- adjuvanted influenza subu-
nit vaccine has been shown to improve immunogenicity 
and to elicited good immune responses and protective 
antibody  [28,  91,  92]. Several studies estimated safety, 
tolerability and immunogenicity of intradermal influenza 
vaccine, the majority of which were conducted in elderly 
population; only one study was conducted on a population 
of immunocompromised patients. A dose-response rela-
tionship together with more efficient antibody response 
for intradermal vaccine was demonstrated using only a 
fifth of the normal dose evaluating the humoral response 
of intradermal influenza vaccination versus intramuscular 
vaccination. Local skin reactions can be used as predic-
tors for the success of vaccination by identifying patients 
who may need a booster [54].
In general, the immunogenicity studies have shown 
encouraging results for the HIV positive subjects with 
antibody titres protecting, data on safety and tolerabil-
ity are encouraging reporting only a few cases of seri-
ous effects on the population considered (about 10% 
of patients).
Definitely the most promising data concern the use of 
vaccine adjuvants, in particular with MF59®, and the 
use of new vaccine intradermal administration should be 
more extensively examined.
In the light of data reported in this review, there still is 
much to do about vaccination in immunocompromised 
patients. More extensive effectiveness studies are need-
ed, to assess the impact of influenza vaccination and to 
prevent complications associated with it.
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Introduction
Over the last years medicine has progressed very rap-
idly. Communicable diseases, which were the leading 
causes of mortalities, are not anymore, especially in 
developed countries. Currently, non-communicable dis-
eases are more prevalent, and most of them are related 
to changes in our daily habits and degenerative process-
es. Most of these diseases are chronic, need continuous 
care and treatment with limited improvement and high 
costs [1-3]. 
The General Assembly of the United Nations in its reso-
lution 65/238 recognized the primary role and responsi-
bility of Governments in responding to the challenge of 
non-communicable diseases and the essential need for 
the efforts and engagement of all sectors of society to 
generate an effective response [2].
Special emphasis has been concentrated on pharmaco-
logical treatments for most of chronic non-communica-
ble diseases with the challenge to discover new drugs for 
treating, in most cases, chronic irreversible degenerative 
diseases associated with aging. Little care was given to 
non-pharmacological lines of treatment [3]. 
Arterial hypertension 
Worldwide hypertension is the most frequent chronic 
disease among aged population It is estimated that 
35% of the general population over 40 years old suf-
fer idiopathic arterial hypertension and need treatment 
for life  [4,  5]. Over the last years pharmacological 
treatment has revolutionized rapidly. Angiotensin-
converting-enzyme inhibitors (ACEIs) have replaced 
beta-blockers in many cases. The current scientific 
debate is about indications, effectiveness, safety and 
cost-effectiveness of angiotensin receptor blocker 
(ARB) and AECI. Recently ARB is taking its place 
between known antihypertensive drugs especially in 
patients with other chronic diseases like renal insuf-
ficiency  [6,  7]. Non-pharmacological measures for 
treatment of hypertension are well-known and include 
diet control with low salt diet and cholesterol diet, 
tobacco cessation, weight control and physical exer-
cises [8-11]. It is estimated that 30% of hypertensive 
patients can control their blood pressure following 
non-pharmacological measures without the need for 
any antihypertensive drugs. Little attention is given to 
these basic non-pharmacological measures [12].
Diabetes mellitus
Over the last 30 years the number of Diabetes Mel-
litus (DM) patients and its prevalence are rapidly ris-
ing [13]. Ginter and Simko (2010) reported that in the 
second half of the 20th century it became obvious that a 
relentless increase in DM type 2 affecting the economi-
cally affluent countries is gradually afflicting also the 
developing world [14]. Oral antidiabetics drugs are vari-
ous and are very effective in DM type 2. However, all 
these drugs have several side effects, which are usually 
related to other underlying pathologies in the same pa-
tient [15]. DM type I is treated with insulin, which has 
been revolutionized over the last 10 years, with various 
forms of insulin and modes of administration [14, 16]. 
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Summary
Over the last years medicine has progressed very rapidly. Com-
municable diseases, which were the leading causes of mortali-
ties, are not anymore, especially in developed countries. Cur-
rently, non-communicable diseases are more prevalent, and 
most of them are related to changes in our daily habits and 
degenerative processes. Most of these diseases are chronic, 
need continuous care and treatment with limited improvement 
and high costs. The General Assembly of the United Nations in 
its resolution 65/238 recognized the primary role and respon-
sibility of Governments in responding to the challenge of non-
communicable diseases and the essential need for the efforts 
and engagement of all sectors of society to generate an effec-
tive response. Special emphasis has been concentrated on phar-
macological treatments for most of chronic non-communicable 
diseases with the challenge to discover new drugs for treating, 
in most cases, chronic irreversible degenerative diseases asso-
ciated with aging. Little care was given to non-pharmacological 
lines of treatment. 
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